Intellia Therapeutics, Inc. (NASDAQ:NTLA) and ReCode Therapeutics have announced a collaborative effort to develop innovative genomic medicines for cystic fibrosis (CF), a genetic disease that affects various organs, notably the lungs and digestive system.

CF results from mutations in the CFTR gene, causing the production of thick mucus and leading to severe complications like respiratory failure and infections. The partnership aims to utilize Intellia's expertise in CRISPR-based gene editing and ReCode's tissue-specific delivery platform to develop precise therapies to correct CF-causing mutations.

Intellia will employ its CRISPR-based gene editing platform and DNA writing technology to design the therapeutic strategy and research-grade components. ReCode will lead subsequent preclinical and clinical development, as well as global commercialization for select programs resulting from the collaboration.

The initial focus will be on addressing CF in patients with limited treatment options, with potential expansion of the collaboration in the future. Intellia stands to receive development and commercial milestone payments, as well as royalties on sales. Additionally, Intellia retains the option to lead commercialization in the U.S. for specific programs.

Both companies are optimistic about the collaboration's potential to accelerate the development of therapies for CF patients. Intellia's President and CEO, John Leonard, underscores the company's commitment to expanding the application of gene editing beyond the liver, emphasizing the significance of the partnership in achieving this goal.

 

Source: businesswire.com

Report Abuse